ENGN enGene Holdings Inc Total Asset Value of Company
enGene Holdings Inc. (ENGN) management is implementing advanced non-sterile gene therapy methods for the treatment of mucous membranes. The company is leveraging the growing interest among urological centers in non-replicating genetic platforms for bladder cancer therapy. This price chart of total assets, valued at 266.91, reflecting trading dynamics, confirms the potential to generate a sustainable cash flow through the implementation of patented methods for treating urological pathologies.
Analytical breakdowns and data insights for company enGene Bio (ENGN)
- stock quotes and analyst forecast:
- market capitalization data:
- issuer book value statistics:
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio enGene Holdings Inc.|ENGN - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio enGene Corp|ENGN - Company Aggregate Debts|Debts to Book Capitalization enGene Corp|ENGN - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings enGene|Interim Coverage Ratio engene.com
- net income and valuation multiples indicators:
Fundamental valuation:enGene Holdings Inc.
Total assets determine the overall resource potential of an enterprise, combining equity and external liabilities. The dynamics of the company's financial asset values allow for an assessment of impairment risk or a decline in capital management efficiency. The calculated level of this metric is based on a reverse analysis of the daily ROA indicator, reflecting the real value of controlled assets. For enGene Holdings Inc. (ENGN), this is a critical indicator for scaling developments in the field of safe non-viral gene therapy delivery.
Key competitors
Total Business Assets ARGX|Aggregate Company Assets BioNTech|Abivax - Total Asset Value of Company|Company Total Assets ADMA|PTGX (Protagonist Corp) - Aggregate Asset Value|Company Total Assets IMVT (Immunovant, Inc.)|Company Total Assets kiniksa.com KNSA|GRFS - Aggregate Company Assets|Aggregate Asset Value ADPT (Adaptive Biotech)|Celldex (CLDX) - Aggregate Company Assets|Cumulative Company Assets Aurinia Corp|BCRX (BioCryst) - Company Total Assets|Company Total Assets veratx.com|Cumulative Company Assets DNTH (Dianthus Therapeutics, Inc.)|PHVS (Pharvaris NV) - Aggregate Asset Value|Company Total Assets ABCL (abcellera.com)|Company Total Asset Base Tourmaline (TRML)|PGEN - Aggregate Company Assets|pharming.com (PHAR) - Cumulative Company Assets|Nektar Therapeutics Inc. (NKTR) - Aggregate Company Assets|Cumulative Company Assets Upstream Bio, Inc.|Cumulative Company Assets ZBIO|Company Total Assets Immunome Bio|Aggregate Company Assets Gossamer Bio, Inc. (GOSS)|kalvista.com - Total Business Assets|Company Total Assets SEPN (Septerna)|Pieris Pharma (PVLA) - Company Assets|Savara Corp - Company Total Assets|Company Assets Rigel Corp|AnaptysBio, Inc. (ANAB) - Aggregate Company Assets|Total Business Assets ATXS|RAPT (RAPT Therapeutics) - Company Total Assets|JBIO - Company Balance Sheet Assets|Company Total Assets ACRS|KYTX - Company Assets|Aggregate Company Assets Tiziana Life Sciences TLSA|CABA: Total Business Assets|Ventyx Biosciences, Inc. - Company Total Assets|Company Assets Theratechnologies, Inc.|AVTX (Avalo Therapeutics Inc.) - Cumulative Company Assets|Eledon Pharmaceuticals, Inc - Aggregate Asset Value|AGEN (Agenus) - Company Total Assets|CLYM: Aggregate Asset Value|Aggregate Company Assets Zura Bio (ZURA)|ATYR - Company Assets|Aggregate Company Assets Adagene Inc. ADAG|ImageneBio - Aggregate Company Assets|Shattuck Therapeutics - Company Total Assets|EQ (Equillium, Inc.) - Total Business Assets|CNTB: Company Total Assets|IMUX - Company Total Asset Base|Aggregate Company Assets Atara Biotherapeutics, Inc.|Total Business Assets IFRX (InflaRx GmbH)|Company Total Assets XFOR|adicetbio.com (ACET) - Company Balance Sheet Assets|Aggregate Company Assets Celularity CELU|Company Total Asset Base INmune Bio Inc (INMB)|BRNS: Cumulative Company Assets|Aggregate Asset Value KZR (Kezar Life Sciences Inc)|SABS: Company Total Assets|AKTX - Company Total Asset Base|Aggregate Company Assets Enlivex Therapeutics Ltd|Total Business Assets QTTB (Q32 Bio Corp)|Company Total Assets GOVX|Cumulative Company Assets Edesa Biotech Corp EDSA|iBio, Inc. - Cumulative Company Assets|Company Total Asset Base Carisma Therapeutics Inc (CARM)|XTL Biopharmaceuticals Ltd. - Company Total Assets|Company Assets Bolt Biotherapeutics|hcwbiologics.com (HCWB) - Aggregate Company Assets|Total Business Assets APVO|AIM (AIM ImmunoTech Inc.) - Company Total Assets|ADTX - Company Balance Sheet Assets|Aggregate Company Assets GRI Bio (GRI)|XORTX Therapeutics Inc - Total Business Assets|Aggregate Company Assets ReShape Lifesciences HIND|REVB (Revelation Biosciences Corp) - Total Asset Value of Company|Indaptus Therapeutics - Company Total Assets|Aggregate Asset Value SCNI (scinai.com)|CALI: Company Total Assets|Affimed N.V. (AFMD) - Company Total Assets|Aggregate Company Assets Allakos Inc|HOOK: Aggregate Asset Value|Aggregate Company Assets IGM Biosciences, Inc. (IGMS)|Cumulative Company Assets iteostherapeutics.com ITOS|Company Total Assets OCEA (Ocean Biomedical)|Company Total Assets TC BioPharm (Holdings) Plc TCBP|THRD: Cumulative Company Assets